Chugai Gets Third US Breakthrough Status, For Hemophilia Antibody
This article was originally published in PharmAsia News
The US FDA has designated Chugai’s ACE910 as a breakthrough therapy for hemophilia A, making the bispecific antibody the first hemophilia treatment to receive the expedited review status, and marking the third project from the Japanese firm to receive the classification.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.